CD274 and non-small cell lung carcinoma: The international, randomized, open-label, phase 3 KEYNOTE-024 trial compared pembrolizumab (administered at a fixed dose of 200 mg every 3 weeks) [7] to the investigator’s choice of cytotoxic chemotherapy as first-line therapy in patients with advanced NSCLC and a PD-L1 TPS of 50% or greater.